Skip to content

Decoding Presymptomatic White Matter Changes in Huntington Disease

Decoding Presymptomatic White Matter Changes in Huntington Disease

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03193099
Acronym
Win-HD
Enrollment
60
Registered
2017-06-20
Start date
2017-07-11
Completion date
2019-12-30
Last updated
2020-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Huntington Disease, White Matter Alterations

Brief summary

WIN-HD is a monocentric longitudinal study comparing premanifest Huntingtin (HTT) mutation carriers and non HTT mutation carriers to determine that white-matter atrophy occurs far earlier than clinical onset in HD using Diffusion-weighted Nuclear Magnetic Resonance (N spectroscopy (DWS) and Diffusion Tensor Imaging (DTI). The investigators will recruit up to 20 premanifest HTT mutation carriers (15 completed) and up to 20 non HTT mutation carriers (15 completed). It is important to have those 2 populations in order to compare our results and determine if there are significant white-matter changes far from the onset of HD. Therefore, non HTT mutation carriers will be age and gender matched to premanifest HTT mutation carriers. In order to test the hypothesis, the study has 2 visits with a year interval. This study is based on 4 principal criteria: 1. Imaging criteria 2. Clinical and neurological criteria 3. Psychological criteria 4. Behavioral criteria

Interventions

OTHERBrain imaging

Volume, DWS and DTI

STAI (Spielberger state and Trait Anxiety Inventory) A and B, BDI-II (Beck Depression Inventory), MINI (Mini-International Neuropsychiatric Interview) and MINI-SEA (mini Social cognitive and Emotional Assessment)

BEHAVIORALBehavioural assessments

Computerized game

Sponsors

University College, London
CollaboratorOTHER
Institut National de la Santé Et de la Recherche Médicale, France
Lead SponsorOTHER_GOV

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* For presymptomatic individuals: * Genetic test available with CAG (Cytosine-Adenine-Guanine) repeat length \> 36 in HTT gene * UHDRS score \<5 * Burden score \<250 * For controls: \- Genetic test available with CAG repeat length ≤ 36 in HTT gene * Common inclusion criteria for presymptomatic individuals and controls (age-matched and gender-matched with presymptomatic individuals and but without any familial relationship): * At least 18 years of age * Capacity to consent * Signature of the informed consent * Covered by social security * Ability to undergo MRI scanning Non-Inclusion Criteria: * Under the age of 18 years of age * Contra-indications to MRI examination (metallic implant, pacemaker, artificial heart valve, brain vascular malformation, aneurysm clips, exposed by metallic fragments, artificial implants, peripheral or neuronal stimulator, insulin pump, intravenous catheter, epilepsy, person with an history of seizure, metallic contraceptive device, permanent eyelid make up, claustrophobia,…) * Unwillingness to be informed in case of abnormal MRI (with a significant medical anomaly) * History of severe head injury * History of neurological disorder or presence of neurological disorder * Participation in a drug trial or exclusion period of another study * Pregnancy or breastfeeding * Inability to understand information about the protocol * Person deprived of their liberty by judicial or administrative decision * Person under legal protection (legal guardianship, tutelage or maintenance of justice) * Person without any protection and unable to consent

Design outcomes

Primary

MeasureTime frame
Detection by Diffusion-weighted spectroscopy of abnormal white matter changes prior to the onset of Huntington disease comparing HTT mutation carriers and non HTT mutation carriers over one yearone year

Secondary

MeasureTime frame
Detection by Diffusion Tensor Imaging of abnormal white matter changes prior to the onset of Huntington disease comparing HTT mutation carriers and non HTT mutation carriers over one year.one year
Detection by Diffusion Tensor Imaging white matter changes over one year as an intersubject evolution.one year
Detection by Diffusion-weighted spectroscopy of abnormal white matter changes over one year as an intersubject evolutionone year
Detection of choice rates and time differences in the behavioral task comparing HTT mutation carriers and non HTT mutation carriers over one year.one year
Detection of time differences in the behavioral task comparing HTT mutation carriers and non HTT mutation carriers over one year.one year
Detection of abnormal scores from psychological tests to assess possible early non motor changes and their intersubject evolution over one year.one year

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026